25 microgramme
Sponsors
Amolyt Pharma
Conditions
Hypoparathyroidism
Phase 3
A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)
WithdrawnCTIS2022-503126-12-00
Target: 12Updated: 2023-07-25
A phase 3 multicenter, randomized, placebo-controlled, double‑blind study to evaluate the efficacy and safety of eneboparatide (AZP‑3601), a parathyroid hormone receptor agonist, in patients with chronic hypoparathyroidism (CALYPSO)
RecruitingCTIS2022-503126-12-01
Start: 2024-01-05Target: 112Updated: 2025-07-28